CFN Media

July 13, 2017 09:00 ET

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

SEATTLE, WA--(Marketwired - Jul 13, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article covering InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) new research and development deal with ATERA SAS of France and the company's development of INM-750 for the treatment of epidermolysis bullosa (EB).

Epidermolysis Bullosa
Epidermolysis bullosa is a group of rare diseases that causes the skin to blister or tear in response to minor injury, heat, friction, scratching, or adhesive tape. In the worst cases, these blisters may occur inside the body in the mouth or intestines. The inherited condition is caused by a defect in the anchoring between the epidermis and dermis, which results in friction and skin fragility that can cause blisters and painful sores.

There is no cure for the disease and treatment options are aimed at alleviating symptoms, such as infection and itching, as well as preventing pain and re-healing wounds. Recently, Amicus Therapeutics Inc. acquired Scioderm's SD-101 for the treatment of skin blistering and lesions in a deal that could be worth more than $847 million after completing a Phase IIB study in 48 patients and is now in its Phase III trials.

InMed Pharma's INM-750 product program represents a compelling alternative to SD-101 for several reasons. First, the cannabinoid compound addresses five core treatment targets -- inflammation, wound healing, skin regeneration, itching, and pain -- rather than just blistering and lesions. Second, there are early indications that INM-750 could potentially help reverse the painful condition by addressing the underlying cause rather than just treat the symptoms.

Cannabinoid compounds have well-documented anti-inflammatory, analgesic, and wound healing promoting properties via several mechanisms of action. InMed Pharma's proprietary Bioinformatics Database Assessment Tool predicted cannabinoid combinations that address the hallmark EB properties, as well as cannabinoids that regulate the expression of various keratins that might compensate for the dysfunctional proteins that cause EB.

Progressing the Study
InMed Pharma's new research and development agreement with ATERA SAS will support the development of its INM-750 for epidermolysis bullosa. The proprietary topical cannabinoid product helps modulate keratin levels in patients with EB while simultaneously addressing inflammation, wound healing, skin regeneration, itching, and pain. Management aims to begin Phase I clinical trials next year after completing additional pre-clinical work.

ATERA specializes in the development, validation, manufacturing, and commercialization of advanced tissue models as reliable, cost-effective, high-quality, and more conscientious alternatives for animal studies. Under the agreement, ATERA will develop 3D human skin models of EB to evaluate the efficiency of INM-750 as well as investigate the beneficial effects of topically applied INM-750 at ultra-structural cellular and molecular levels.

"INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including accelerated wound healing and a reduction in pain, itch, and inflammation," said InMed Pharma CSO Dr. Sazzad Hossain. "This project with ATERA is designed to assess the potential of INM-750 to have an impact in disease reversal, further supporting our current data indicating up-regulation in specific keratins in the skin."

The company has also conducted several in vitro and in vivo assays showing early positive results of INM-750 in treating EB conditions, but the deal with ATERA will provide a much more accurate indication of whether the therapy will be successful in meeting both symptomatic improvement as well as disease reversal outcomes. If so, the company could be sitting on a valuable drug following the $850+ million acquisition of SD-101 that addresses fewer underlying symptoms and provides no potential curative activity.

Please follow the link to read the full article:

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media
CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information